Authored By: Sarah
10 Feb 2023

Celiac Diseases Drugs Market Share, Segments, Trends, Growth, and Geography- Analysis, and Forecast 2022-2026

The celiac disease drugs market share is forecast to reach USD 601.57 million, after growing at a CAGR of 16.95% during 2021-2026. The higher consumption of gluten-containing food is analyzed to boost the celiac disease drug market growth. Moreover, inorganic growth strategies are the major trend enhancing the overall market demand for celiac disease drugs during the forecast period.   

Get a snapshot on the celiac diseases drugs market analysis: Unlock the Sample Report 

Browse Technavio's 120-page report and in-depth TOC on "Celiac Diseases Drugs Market by therapy type (first line of treatment and second line of treatment) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

View detailed Table of Contents Here: https://www.technavio.com/report/celiac-diseases-drugs-market-industry-analysis

Celiac Diseases Drugs Market Share, Segments, Trends, Growth, and Geography- Analysis, and Forecast 2022-2026

Therapy type: 

  • First line of treatment: The celiac disease drug market share growth by the first line of treatment segment has been significant. This segment is expected to grow at lucrative rates due to the robust pipeline.

  • Second line of treatment

Geography: 

  • North America: 58% of the market’s growth will originate from North America. The rising prevalence of celiac disease, growing awareness of celiac diseases, presence of key vendors, and a strong pipeline of drugs in the region will facilitate the celiac diseases drugs market growth in North America over the forecast period.

  • Europe

  • Asia

  • Rest of the World (ROW)

Key Takeaways: 

  • The celiac disease drugs market size will witness a YOY Growth Rate of 16.35% in 2022.  

  • Poor diagnosis will be a major challenge for the celiac disease drugs market during the forecast period. 

  • Major key celiac diseases drugs market players include: 9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Immunogenics LLC, Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, Zedira GmbH, and Artielle Immunotherapeutics Inc  

  • The report illustrates the lifecycle of the market, focusing on the adoption rates of the major regions such as the North America, Europe, Asia, and the Rest of the World (ROW). 

Download the PDF sample report for highlights on the market size, growth momentum, regional growth opportunities, vendor analysis, and other factors influencing the market growth. 

Key data covered in the Celiac Diseases Drugs Market report 

  • Precise market size estimation during the forecast period 2022-2026.  

  • CAGR of the celiac diseases drugs market forecast during 2022-2026.  

  • Market-level data on units, average selling prices, and values of the celiac diseases drugs market share.  

  • Prediction of the upcoming trends, drivers, and factors that challenge the growth of the celiac disease drugs market.  

  • Celiac diseases drugs industry growth across North America, Europe, Asia, and the Rest of the World (ROW). 

Read News Read Less
Interested in this report?
Get your sample now!
Technavio